ArticleHemaSphere2026

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

Luca De Carolis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.